Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Background The alpha-emitter radium-223 (Ra-223) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. We aimed to study mature outcomes from a randomised, multicentre, phase II study of Ra-223. Methods Patients with hormone-refractory prostate cancer and bone pain needing external-beam radiotherapy were assigned to fou